Bristol-Myers Squibb (NYSE:BMY) has been assigned a $49.00 price objective by investment analysts at BMO Capital Markets in a research report issued on Monday. The firm presently has a “sell” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price indicates a potential downside of 22.57% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Jefferies Group restated a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target on the stock in a report on Wednesday, September 27th. Goldman Sachs Group restated a “buy” rating and issued a $65.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. UBS restated a “buy” rating and issued a $72.00 price target (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, Citigroup upped their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $64.93.

Bristol-Myers Squibb (NYSE BMY) opened at $63.28 on Monday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market cap of $103,144.84, a PE ratio of 21.29, a PEG ratio of 2.39 and a beta of 1.18. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.77 earnings per share. research analysts predict that Bristol-Myers Squibb will post 2.99 EPS for the current year.

In related news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Tradewinds Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. Atlantic Trust LLC purchased a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC raised its position in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the last quarter. Proficio Capital Partners LLC raised its position in shares of Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 504 shares during the last quarter. Finally, American National Bank raised its position in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 225 shares during the last quarter. 69.82% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb (BMY) PT Set at $49.00 by BMO Capital Markets” was first published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-bmy-pt-set-at-49-00-by-bmo-capital-markets/1760677.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with Analyst Ratings Network's FREE daily email newsletter.